Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
The safety & effectiveness of combining extended release niacin + laropiprant + simvastatin (MK-0524B) in the management of cholesterol levels
1. Evaluate the LDL-C-lowering effects of ERN/LRPT/SIM 2 g/40 mg compared to ERN/LRPT 2 g coadministered with simvastatin 40 mg. Hypothesis: ERN/LRPT/SIM 2 g/40 mg is equivalent to ERN/LRPT 2 g coa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Phase II Trial of MK-3475 in Subjects with mCRPC with Prior Chemotherapy
1) Objective: To estimate the objective response rate (ORR) by RECIST 1.1 and duration of response (DOR) by PCWG3-modified RECIST 1.1 in subjects with measurable disease (Cohorts 1 and 2), assessed by...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Phase III Study of 2 doses of V503 in 9 to 14 year-olds Compared to Young Women Klinické hodnocení zkoumající snášenlivost a imunitní odpověď organizmu na podání 2 dávek vakcíny V503, po očkování dětí (9 až 14 let) ve srovnání s mladými dívkami (16 až 26 let)
1)To demonstrate administration of a 2-dose 9-valent HPV L1 VLP vaccine at Day 1 & Month 6 induces non-inferior GMTs for serum anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18, anti-HPV 31, anti-HPV ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance
Base study: 1)To evaluate the antiretroviral activity of MK-1439A as measured by the proportion of subjects achieving HIV -1 RNA <50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48. 2)To e...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control
After 54 weeks, to assess the effect of sitagliptin compared with glipizide on HbA1c; After 54 weeks, to assess the effect of sitagliptin compared with glipizide on the incidence of hypoglycemic event...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Therapy
Part 1 • To define the dose limiting toxicities(DLT) and maximum tolerated dose(MTD) of dalotuzumab when administered as monotherapy to children from 3 to less than 18 years of age with advanced solid...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
MK-8228 vs. Placebo in Prevention of CMV infection in HSCT Recipients
To evaluate the efficacy of MK-8228 in the prevention of clinically significant CMV infection through Week 24 (~6 months) post-transplant following administration of MK-8228 or placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids
Main objective: To determine whether ZOSTAVAX™ [zoster vaccine live (Oka/Merck)] has an acceptable safety profile when administered to patients who are receiving chromic/maintenance corticosteroid th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients with High Bad Cholesterol or Low Good Cholesterol (HDL-C)
1. To evaluate the efficacy of anacetrapib 100 mg for 24 weeks relative to placebo on plasma concentrations of LDL C (BQ method). 2. To evaluate the efficacy of anacetrapib 100 mg for 24 weeks relati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16